Herzog TJ - Search Results

1

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.

Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Rocconi RP, et al. Among authors: herzog tj. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. Lancet Oncol. 2020. PMID: 33271095 Clinical Trial.

2

Topotecan in platinum- and paclitaxel-resistant ovarian cancer.

Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Swisher EM, et al. Among authors: herzog tj. Gynecol Oncol. 1997 Sep;66(3):480-6. doi: 10.1006/gyno.1997.4787. Gynecol Oncol. 1997. PMID: 9299264 Clinical Trial.

3

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog TJ, Rose PG. Markman M, et al. Among authors: herzog tj. Gynecol Oncol. 1999 Dec;75(3):444-6. doi: 10.1006/gyno.1999.5640. Gynecol Oncol. 1999. PMID: 10600304 Clinical Trial.

4

Synchronous ovarian metastases at the time of laparotomy for colon cancer.

Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Wright JD, et al. Among authors: herzog tj. Gynecol Oncol. 2004 Mar;92(3):851-5. doi: 10.1016/j.ygyno.2003.12.017. Gynecol Oncol. 2004. PMID: 14984952

5

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

6

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.

Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Gallion H, et al. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201. doi: 10.1111/j.1525-1438.2006.00301.x. Int J Gynecol Cancer. 2006. PMID: 16445633

7

The role of maintenance therapy and novel taxanes in ovarian cancer.

Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. Herzog TJ, et al. Gynecol Oncol. 2006 Aug;102(2):218-25. doi: 10.1016/j.ygyno.2005.12.001. Epub 2006 Feb 7. Gynecol Oncol. 2006. PMID: 16460787 Review.

8

A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.

Herzog TJ, Coleman RL, Guerrieri JP Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. Herzog TJ, et al. Am J Obstet Gynecol. 2006 Aug;195(2):445-53. doi: 10.1016/j.ajog.2006.01.039. Epub 2006 Apr 19. Am J Obstet Gynecol. 2006. PMID: 16626607 Clinical Trial.

9

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. Gossner G, et al. Among authors: herzog tj. Gynecol Oncol. 2006 Oct;103(1):212-8. doi: 10.1016/j.ygyno.2006.02.026. Epub 2006 May 3. Gynecol Oncol. 2006. PMID: 16677696

10

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Herzog TJ, et al. Gynecol Oncol. 2006 Nov;103(2):637-41. doi: 10.1016/j.ygyno.2006.04.014. Epub 2006 Jun 15. Gynecol Oncol. 2006. PMID: 16781766 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

406 results

Search Page

Filters